Daiwa Health Development has introduced double strength BRM4™, a 500mg, 60 count version of its patented immune enhancing complex to the health professional marketplace. BRM4™, with its active ingredient Rice Bran Arabinoxylan Compound (RBAC), has been clinically shown to triple Natural Killer (NK) cell activity, increase T and B lymphocytes and demonstrate vital antioxidant and anti-inflammatory action.
RBAC, a polysaccharide dietary fiber derived from rice bran, is modified by a Shiitake mushroom enzyme using a patented biotechnology process. As an immune modulator, BRM4™ retains its effectiveness over time. Clinical trials have shown BRM4 is safe with no side effects. In over 12 years of worldwide use, there have been no reported cases of drug interactions. BRM4™ is recognized as the gold standard immune product worldwide for people with seriously compromised immune systems.
BRM4™ in a 250mg dosage, 60 count bottle, has been available through physicians for over 10 years. In pre-clinical studies, the power of BRM4™ multiplies T cell levels up to 200%. The enhanced activity of helper T cells promotes the proliferation of cytotoxic T and B cells for essential immune support. Helper T cells also signal plasma B cells when they encounter their cognate antigen to secure a health production of antibodies. Furthermore, BRM4™ supports the body’s natural production of cytokines to control inflammatory response.
Double Strength BRM4™ is now available to health professionals in the U.S. For more product and ordering information call 877.434.3633 or email [email protected].
Los Angeles-based Daiwa Health Development, Inc. is a subsidiary of Daiwa Pharmaceutical Co. Ltd. based in Tokyo, Japan. Daiwa has become a leading research and manufacturing company, striving to create new value in the field of bioscience. Daiwa focuses on the manufacturing and distribution of nutraceuticals, functional foods and cosmetics.